Results 81 to 90 of about 6,250 (152)

Computational strategies to address therapeutic resistance in estrogen receptor‐positive breast cancer: A narrative review of molecular docking, molecular dynamics simulations, and emerging therapeutic targets

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Computational drug discovery integrates molecular docking, molecular dynamics simulations, and translational clinical targeting to identify next‐generation therapeutics that overcome endocrine resistance in ER‐positive breast cancer. Combined with multi‐omics, artificial intelligence, and biomarker‐guided precision oncology, these approaches accelerate
Emmanuel Ifeanyi Obeagu, Yaregal Asres
wiley   +1 more source

Letrozole removal resulted in fewer differentially abundant bacterial genera in placebo versus letrozole mice.

, 2019
DESeq2 differential abundance results were expressed as log2 fold change to compare placebo- and letrozole-treated female mice before (A) and after pellet removal (B).
Bryan S. Ho (7444598), Lillian Sau (6468299), Scott T. Kelley (7444601), Varykina G. Thackray (7444604), Pablo Arroyo (316123)   +4 more
core   +1 more source

Effects of short‐course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor‐positive, HER2‐negative breast cancer

Histopathology, Volume 89, Issue 4, Page 670-686, October 2026.
Short‐course preoperative endocrine therapy induces histopathological and immunophenotypic changes in oestrogen receptor‐positive, HER2‐negative breast cancer. Proliferative response is independently associated with baseline genomic risk (MammaPrint) and progesterone receptor expression.
Claudia Grosse, Alexandra Grosse, Petar Noack, Caroline Ines Preuss, Heike Kathleen Schwarz, Bruno Schneeweiss, Thomas Gitter, Peter Schrenk, Rupert Langer   +8 more
wiley   +1 more source

Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review

, 2009
Alain MonnierInstitut Régional Fédératif du Cancer (IFRC), Centre Hospitalier Belfort-Montbéliard, Montbéliard, FranceAbstract: Aromatase inhibitors (AIs) are becoming more widely used than tamoxifen
Alain Monnier
core  

Palbociclib and Letrozole in Advanced Breast Cancer

, 2016
BACKGROUND A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor ...
Lu, Dongrui R., Gelmon, Karen, Jones, Stephen, Randolph, Sophia, Rugo, Hope S., Slamon, Dennis J., Finn, Richard S., Harbeck, Nadia, Gauthier, Eric, Moulder, Stacy, Martin, Miguel, Dieras, Veronique, Lipatov, Oleg N., Im, Seock-Ah, Walshe, Janice M.   +14 more
core   +1 more source

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR‐Positive, HER2‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER2− breast ...
Xiaopei Dong, Fan Li, Yang Yuan, Hua Song, Yingzhe Wang, Yi Hao, Yinping Dong, Tao Wang, Li Bian, Shaohua Zhang, Jianbin Li   +10 more
wiley   +1 more source

Prevalence and Determinants of Depression, Anxiety, and Quality of Life in Patients With Breast Cancer in Saudi Arabia: A Focus on Adjuvant Pharmacotherapy

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background and Aim While psychological distress is a well‐documented concern among cancer patients, the prevalence and severity of depression and anxiety in breast cancer patients in Saudi Arabia remain insufficiently explored. This study aimed to evaluate depression, anxiety, and quality of life (QoL) among patients with breast cancer ...
Mahmoud S. Abdallah, Ahmed R. Gardouh, Zafaran Khalid Abuaeaaq, Amal Mohammad Badawoud   +3 more
wiley   +1 more source

Use of letrozole and clomiphene citrate combined with gonadotropins in clomiphene-resistant infertile women with polycystic ovary syndrome: a prospective study

, 2015
Wenyan Xi,1 Shankun Liu,2 Hui Mao,1 Yongkang Yang,1 Xiang Xue,1 Xiaoning Lu1 1The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an City, Shaanxi, 2Taian City Central Hospital, Shandong, Taian, People’s Republic of  ...
Xi W, Yang Y, Lu X, Mao H, Liu S, Xue X
core  

A prospective double-blinded, randomized, placebo-controlled trial on the use of letrozole pretreatment with misoprostol for second-trimester medical abortion

, 2011
Background: The aim of this randomized trial was to evaluate the abortion rate of combined regimen of letrozole and misoprostol in second-trimester abortion.
Ho, PC, Lee, VCY, Tang, OS, Ng, EHY, Yeung, WSB   +4 more
core   +1 more source

Bushen Huatan Formula Ameliorates Early Chronic Low‐Grade Inflammation in Obese PCOS Via the TLR4/NF‐κB Signaling Pathway: An Integrated Network Pharmacology and Experimental Study

Immunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
ABSTRACT Objective This study used an integrated network pharmacology and experimental strategy to investigate how Bushen Huatan Formula (BHF) mitigates early‐stage chronic low‐grade inflammation in obese polycystic ovary syndrome (PCOS). Methods Candidate components and targets of BHF were retrieved from the TCMSP database, and protein–protein ...
Jianing Zhang, Fangyun Gu, Yunyun Li, Xiaoling Feng, Hongying Kuang, Fang Xu, Miao Sun   +6 more
wiley   +1 more source